The past, present, and future of non-viral CAR T cells
A Moretti, M Ponzo, CA Nicolette… - Frontiers in …, 2022 - frontiersin.org
Adoptive transfer of chimeric antigen receptor (CAR) T lymphocytes is a powerful technology
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …
that has revolutionized the way we conceive immunotherapy. The impressive clinical results …
Comprehensive review of CRISPR-based gene editing: mechanisms, challenges, and applications in cancer therapy
M Chehelgerdi, M Chehelgerdi… - Molecular cancer, 2024 - Springer
The CRISPR system is a revolutionary genome editing tool that has the potential to
revolutionize the field of cancer research and therapy. The ability to precisely target and edit …
revolutionize the field of cancer research and therapy. The ability to precisely target and edit …
High-yield genome engineering in primary cells using a hybrid ssDNA repair template and small-molecule cocktails
Enhancing CRISPR-mediated site-specific transgene insertion efficiency by homology-
directed repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with …
directed repair (HDR) using high concentrations of double-stranded DNA (dsDNA) with …
Lipid Nanoparticle-Mediated Hit-and-Run Approaches Yield Efficient and Safe In Situ Gene Editing in Human Skin
J Bolsoni, D Liu, F Mohabatpour, R Ebner… - ACS …, 2023 - ACS Publications
Despite exciting advances in gene editing, the efficient delivery of genetic tools to
extrahepatic tissues remains challenging. This holds particularly true for the skin, which …
extrahepatic tissues remains challenging. This holds particularly true for the skin, which …
A highly efficient transgene knock-in technology in clinically relevant cell types
AG Allen, SQ Khan, CM Margulies… - Nature …, 2024 - nature.com
Inefficient knock-in of transgene cargos limits the potential of cell-based medicines. In this
study, we used a CRISPR nuclease that targets a site within an exon of an essential gene …
study, we used a CRISPR nuclease that targets a site within an exon of an essential gene …
Homology-independent targeted insertion (HITI) enables guided CAR knock-in and efficient clinical scale CAR-T cell manufacturing
H Balke-Want, V Keerthi, N Gkitsas, AG Mancini… - Molecular Cancer, 2023 - Springer
Abstract Background Chimeric Antigen Receptor (CAR) T cells are now standard of care
(SOC) for some patients with B cell and plasma cell malignancies and could disrupt the …
(SOC) for some patients with B cell and plasma cell malignancies and could disrupt the …
sustainable clinical development of CAR-T cells–switching from viral transduction towards CRISPR-Cas gene editing
T cells modified for expression of Chimeric Antigen Receptors (CARs) were the first gene-
modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered …
modified cell products approved for use in cancer immunotherapy. CAR-T cells engineered …
Combining different CRISPR nucleases for simultaneous knock-in and base editing prevents translocations in multiplex-edited CAR T cells
Background Multiple genetic modifications may be required to develop potent off-the-shelf
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
chimeric antigen receptor (CAR) T cell therapies. Conventional CRISPR-Cas nucleases …
A review on CRISPR/Cas: a versatile tool for cancer screening, diagnosis, and clinic treatment
X Yang, B Zhang - Functional & Integrative Genomics, 2023 - Springer
Cancer is one of the leading causes of death worldwide and it has the trend of increase
incidence. However, in the past decades, as quickly developed new technologies and …
incidence. However, in the past decades, as quickly developed new technologies and …
[HTML][HTML] Production and characterization of virus-free, CRISPR-CAR T cells capable of inducing solid tumor regression
Background Chimeric antigen receptor (CAR) T cells have demonstrated high clinical
response rates against hematological malignancies (eg, CD19+ cancers) but have shown …
response rates against hematological malignancies (eg, CD19+ cancers) but have shown …